Biotechnology

Vicore Announces Additional Subscription Undertaking from HealthCap

September 17, 2024 2:20 AM

STOCKHOLM, SE / ACCESSWIRE / September 17, 2024 / Vicore Pharma Holding (STO:VICO) THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS...

Read more

ONI Expands Horizons: Entering the Lipid Nanoparticle Research Market

September 16, 2024 9:00 AM

SAN DIEGO, CA / ACCESSWIRE / September 16, 2024 / ONI, a leader in super-resolution microscopy technology, is excited to announce its strategic entry into the lipid nanoparticle (LNP) research sector. This move showcases ONI's commitment to driving innovation in therapeutic delivery systems crucial for mRNA vaccines, gene therapies, and personalized medicine. Lipid nanoparticles represent a groundbreaking approach to encapsulating and...

Read more

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

September 16, 2024 8:20 AM

Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor Types Prolonged stable disease lasting >11 months demonstrated in Breast Cancer Patient Favorable Pharmacokinetics, Safety and Tolerability Observed Data Presented at the European Society of Medical Oncology on September 14, 2024 LUND, SE / ACCESSWIRE / September 16, 2024 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm:ATORX) and Aptevo Therapeutics ("Aptevo")...

Read more

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

September 16, 2024 7:00 AM

BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it has entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody,...

Read more

BioInvent and Transgene’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments

September 14, 2024 6:00 AM

LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / BioInvent International (STO:BINV) Preliminary data presented at ESMO 2024 demonstrate BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma, BT-001 was able to modulate the tumor microenvironment, turning a "cold" tumor to "hot", enhancing the potential of T cell infiltration and a shift to PD(L)-1 positivity...

Read more

Moolec Received NASDAQ Bid Price Letter

September 13, 2024 6:30 PM

LUXEMBOURG / ACCESSWIRE / September 13, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today that it received a letter (the "Nasdaq Bid Price Letter") from Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's ordinary shares has been below the minimum $1.00 per share required for continued listing on The Nasdaq...

Read more

Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024

September 13, 2024 8:20 AM

LUND, SE / ACCESSWIRE / September 13, 2024 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm:ATORX) and Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO) today announced that positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 will be presented in a poster session on Saturday, September 14, 2024, at the European Society for Medical Oncology (ESMO) Annual Congress 2024, taking place September 13th...

Read more

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

September 13, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / September 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has made available two video segments from its August 8th symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam,...

Read more

Correction: Q1 Interim Report May-July 2024/2025

September 12, 2024 4:50 AM

Correction due to missing MAR-legend UPPSALA, SE / ACCESSWIRE / September 12, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Significantly increased sales in the USA and much improved cash flow SEK t Q1 24/25 Q1 23/24 May-April 23/24 Net sales 1,714 1,766 7,290 Operating profit (loss) -23,562 -32,192 -126,845 Earnings per share after dilution -0.27 -0.70 -2.14 Number of shares at the end of the period* 84,055,560 45,741,394...

Read more

BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence(R) for the Treatment of non-Hodgkin's Lymphoma

September 12, 2024 2:50 AM

First patient enrolled in Phase 2a study arm combining BI-1206 with rituximab and acalabrutinibwith initial data expected YE 2024 Clinical supply agreement for acalabrutinib with AstraZeneca in place LUND, SE / ACCESSWIRE / September 12, 2024 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer...

Read more

Q1 Interim Report May-July 2024/2025

September 12, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / September 12, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Significantly increased sales in the USA and much improved cash flow SEK t Q1 24/25 Q1 23/24 May-April 23/24 Net sales 1,714 1,766 7,290 Operating profit (loss) -23,562 -32,192 -126,845 Earnings per share after dilution -0.27 -0.70 -2.14 Number of shares at the end of the period* 84,055,560 45,741,394 84,055,560 Cash and cash equivalents...

Read more

Tesla BioHealing and Cell Biotechnology Co., Ltd. Forge Strategic Partnership to Transform Stem Cell Therapies

September 11, 2024 8:00 PM

BUTLER, PA / ACCESSWIRE / September 11, 2024 / Tesla BioHealing-PA, LLC, a leader in biophoton life force technology, and Cell Biotechnology Co., Ltd, an innovator in stem cell transplantation, have entered a strategic collaboration to revolutionize the development and delivery of stem cell therapies. This partnership, effective September 9, 2024, unites the companies' groundbreaking technologies to significantly enhance patient outcomes by...

Read more

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

September 11, 2024 9:15 AM

Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial study to determine consumer comprehension of the...

Read more

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

September 11, 2024 9:00 AM

FRAMINGHAM, MA / ACCESSWIRE / September 11, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jim Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic, presented at the H.C. Wainwright 26 th Annual Global Investment Conference. The video webcast of...

Read more

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

September 11, 2024 8:15 AM

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / OS Therapies (NYSE American:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced positive data in animal models of ovarian cancer for its first therapeutic candidate developed based upon its proprietary tunable Antibody Drug Conjugate (tADC) platform. The first therapeutic candidate leverages a folate...

Read more

Enalare Therapeutics Receives Additional Funding From BARDA to Further Advance the Development of Agnostic Respiratory Stimulant (ENA-001)

September 10, 2024 8:00 AM

PRINCETON, NJ / ACCESSWIRE / September 10, 2024 / Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care conditions and community health emergencies, today announced that it has received additional funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and...

Read more

Altius Bioventures Launches The CGT Industry Atlas, Mapping out the Cell and Gene Therapy Technology Innovation Landscape

September 10, 2024 8:00 AM

Altius Bioventures is pleased to announce the release of its CGT Industry Atlas, a comprehensive guide outlining its view of the cell and gene therapy technologies landscape, from starting material collection to therapy manufacturing and clinical delivery. The CGT Industry Atlas categorizes the sector into seven core elements, each representing a critical component within the cell and gene therapy ecosystem. "The CGT Industry Atlas is designed...

Read more

Vicore Initiates the Global, Randomized Phase 2b ASPIRE Trial Evaluating the Disease-Modifying Potential of Buloxibutid in Idiopathic Pulmonary Fibrosis

September 10, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / September 10, 2024 / Vicore Pharma Holding (STO:VICO) ASPIRE is a global Phase 2b trial measuring change in FVC from baseline over 52 weeks, the established regulatory endpoint. ASPIRE will enroll 270 patients across 14 countries, including the United States, and will allow patients to remain on background nintedanib standard of care therapy. The advancement of buloxibutid into late-stage development is supported...

Read more

The Center for Immunology Science and Immunology Diagnostics Announce a Major Breakthrough Discovery: DNA-Based Proof of the Disease of Fibromyalgia

September 9, 2024 8:00 AM

Groundbreaking Study Confirms Fibromyalgia as a True Medical Condition with 100% Accuracy Using Unique DNA Genomic Signatures, Offering New Hope for Objective Diagnosis and Treatment.​ LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / A medical study recently published in the highly ranked and prestigious medical and science journal, NATURE-Scientific Reports, (Springer Nature (2024) 14:3949), found that 100% of patients who received a positive...

Read more

BioInvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

September 9, 2024 1:20 AM

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV) Three partial responses (PR) and one stable disease (SD) out of four evaluable patients with Cutaneous T-cell Lymphoma (CTCL) have been observed in the single agent part of the Phase 2a study. Three other patients in the cohort were considered non-evaluable. All patients had progressed after standard therapy. The three responding patients had received 9, 3 and 3...

Read more